Rieger anomaly
diseaseOn this page
Summary
Rieger anomaly (MONDO:0019628) is a disease with 7 cohort genes.
At a glance
- Cohort genes: 7
- ClinVar variants: 8
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | Rieger anomaly |
| Mondo ID | MONDO:0019628 |
| Orphanet | 91483 |
| UMLS | C0265341 |
| MedGen | 78558 |
| GARD | 0016482 |
| MedDRA | 10059198 |
| Is cancer (heuristic) | no |
Data availability: 8 ClinVar variants · 2 GenCC gene-disease records · 2 cell lines.
Disease family
An umbrella term covering 1 Mondo subtype.
Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › anterior segment dysgenesis › iridogoniodysgenesis › Rieger anomaly
Related subtypes (6): congenital microcoria, aniridia-cerebellar ataxia-intellectual disability syndrome, chromosome 6pter-p24 deletion syndrome, bilateral acute depigmentation of the iris, congenital ectropion uveae, FOXC1-related anterior segment dysgenesis
Subtypes (1): anterior segment dysgenesis 4
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
8 retrieved; paginated sample, class counts are floors:
3 conflicting classifications of pathogenicity, 3 likely benign, 1 likely pathogenic, 1 pathogenic
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 492756 | NM_000325.6(PITX2):c.307C>T (p.Gln103Ter) | PITX2 | Pathogenic | criteria provided, single submitter |
| 268022 | 46;XY;t(2;4)(p23;q27)dn | Likely pathogenic | criteria provided, single submitter | |
| 221949 | NM_025074.7(FRAS1):c.3700G>A (p.Ala1234Thr) | FRAS1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 30767 | NM_001379081.2(FREM1):c.1493G>A (p.Arg498Gln) | FREM1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 132723 | NM_000264.5(PTCH1):c.3947A>G (p.Tyr1316Cys) | PTCH1 | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 221947 | NM_024533.4(CHST5):c.737T>C (p.Ile246Thr) | CHST5 | Likely benign | criteria provided, single submitter |
| 221948 | NM_001079520.2(DACT1):c.1899G>C (p.Lys633Asn) | DACT1 | Likely benign | criteria provided, single submitter |
| 132738 | NM_000264.5(PTCH1):c.3889C>T (p.Arg1297Trp) | PTCH1 | Likely benign | criteria provided, multiple submitters, no conflicts |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 25 · Orphanet: 29 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| FOXC1 | Definitive | Autosomal dominant | Axenfeld-Rieger syndrome type 3 | 10 |
| PITX2 | Definitive | Autosomal dominant | Axenfeld-Rieger syndrome type 1 | 15 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| PITX2 | Orphanet:334 | Hereditary atrial fibrillation |
| PITX2 | Orphanet:708 | Peters anomaly |
| PITX2 | Orphanet:782 | Axenfeld-Rieger syndrome |
| PITX2 | Orphanet:91481 | Ring dermoid of cornea |
| PITX2 | Orphanet:91483 | Rieger anomaly |
| PITX2 | Orphanet:98978 | Axenfeld anomaly |
| FOXC1 | Orphanet:250923 | Isolated aniridia |
| FOXC1 | Orphanet:708 | Peters anomaly |
| FOXC1 | Orphanet:782 | Axenfeld-Rieger syndrome |
| FOXC1 | Orphanet:91483 | Rieger anomaly |
| FOXC1 | Orphanet:98978 | Axenfeld anomaly |
| DACT1 | Orphanet:268823 | Occipital encephalocele |
| DACT1 | Orphanet:63260 | Craniorachischisis |
| DACT1 | Orphanet:857 | Townes-Brocks syndrome |
| FRAS1 | Orphanet:2052 | Fraser syndrome |
| FRAS1 | Orphanet:93100 | Renal agenesis, unilateral |
| FREM1 | Orphanet:217266 | BNAR syndrome |
| FREM1 | Orphanet:2717 | Oculotrichoanal syndrome |
| FREM1 | Orphanet:3366 | Non-syndromic metopic craniosynostosis |
| FREM1 | Orphanet:93100 | Renal agenesis, unilateral |
| PTCH1 | Orphanet:220386 | Semilobar holoprosencephaly |
| PTCH1 | Orphanet:2353 | Schilbach-Rott syndrome |
| PTCH1 | Orphanet:280195 | Septopreoptic holoprosencephaly |
| PTCH1 | Orphanet:280200 | Microform holoprosencephaly |
| PTCH1 | Orphanet:377 | Gorlin syndrome |
| PTCH1 | Orphanet:77301 | Monosomy 9q22.3 syndrome |
| PTCH1 | Orphanet:93924 | Lobar holoprosencephaly |
| PTCH1 | Orphanet:93925 | Alobar holoprosencephaly |
| PTCH1 | Orphanet:93926 | Midline interhemispheric variant of holoprosencephaly |
Cohort genes → proteins
7 cohort genes, 7 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 7 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| PITX2 | HGNC:9005 | ENSG00000164093 | Q99697 | Pituitary homeobox 2 | gencc,clinvar |
| FOXC1 | HGNC:3800 | ENSG00000054598 | Q12948 | Forkhead box protein C1 | gencc |
| DACT1 | HGNC:17748 | ENSG00000165617 | Q9NYF0 | Dapper homolog 1 | clinvar |
| FRAS1 | HGNC:19185 | ENSG00000138759 | Q86XX4 | Extracellular matrix organizing protein FRAS1 | clinvar |
| CHST5 | HGNC:1973 | ENSG00000135702 | Q9GZS9 | Carbohydrate sulfotransferase 5 | clinvar |
| FREM1 | HGNC:23399 | ENSG00000164946 | Q5H8C1 | FRAS1-related extracellular matrix protein 1 | clinvar |
| PTCH1 | HGNC:9585 | ENSG00000185920 | Q13635 | Protein patched homolog 1 | clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| PITX2 | Pituitary homeobox 2 | May play a role in myoblast differentiation. |
| FOXC1 | Forkhead box protein C1 | DNA-binding transcriptional factor that plays a role in a broad range of cellular and developmental processes such as eye, bones, cardiovascular, kidney and skin development. |
| DACT1 | Dapper homolog 1 | Involved in regulation of intracellular signaling pathways during development. |
| FRAS1 | Extracellular matrix organizing protein FRAS1 | Involved in extracellular matrix organization. |
| CHST5 | Carbohydrate sulfotransferase 5 | Sulfotransferase that utilizes 3’-phospho-5’-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the transfer of sulfate to position 6 of non-reducing N-acetylglucosamine (GlcNAc) residues and O-linked sugars of mucin-type acceptors. |
| FREM1 | FRAS1-related extracellular matrix protein 1 | Extracellular matrix protein that plays a role in epidermal differentiation and is required for epidermal adhesion during embryonic development. |
| PTCH1 | Protein patched homolog 1 | Acts as a receptor for sonic hedgehog (SHH), indian hedgehog (IHH) and desert hedgehog (DHH). |
Protein-family classification
Druggable: 0 · Difficult: 2 · Unknown: 5 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Transcription factor | 2 | 2.4× | 0.332 |
| Other/Unknown | 5 | 1.3× | 0.332 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| PITX2 | Transcription factor | no | HD, OAR_dom, Homeodomain-like_sf | |
| FOXC1 | Transcription factor | no | Fork_head_dom, TF_fork_head_CS_1, TF_fork_head_CS_2 | |
| DACT1 | Other/Unknown | no | Dapper | |
| FRAS1 | Other/Unknown | no | EGF, VWF_dom, Calx_beta | |
| CHST5 | Other/Unknown | no | Sulfotransferase_dom, Carbohydrate_sulfotransferase, P-loop_NTPase | |
| FREM1 | Other/Unknown | no | C-type_lectin-like, Calx_beta, C-type_lectin-like/link_sf | |
| PTCH1 | Other/Unknown | no | SSD, TM_rcpt_patched, HMGCR/SNAP/NPC1-like_SSD |
Expression context
Cohort genes with no expression data: 0.
7 cohort genes are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 7 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| trigeminal ganglion | 2 |
| biceps brachii | 1 |
| gingiva | 1 |
| gingival epithelium | 1 |
| parotid gland | 1 |
| vena cava | 1 |
| cortical plate | 1 |
| gall bladder | 1 |
| right coronary artery | 1 |
| germinal epithelium of ovary | 1 |
| parietal pleura | 1 |
| renal medulla | 1 |
| duodenum | 1 |
| mucosa of transverse colon | 1 |
| rectum | 1 |
| kidney epithelium | 1 |
| metanephros | 1 |
| smooth muscle tissue | 1 |
| dorsal root ganglion | 1 |
| tibia | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| PITX2 | 166 | broad | marker | gingiva, biceps brachii, gingival epithelium |
| FOXC1 | 267 | ubiquitous | marker | parotid gland, vena cava, trigeminal ganglion |
| DACT1 | 200 | ubiquitous | marker | cortical plate, right coronary artery, gall bladder |
| FRAS1 | 212 | ubiquitous | marker | germinal epithelium of ovary, parietal pleura, renal medulla |
| CHST5 | 117 | tissue_specific | marker | duodenum, rectum, mucosa of transverse colon |
| FREM1 | 171 | broad | marker | kidney epithelium, smooth muscle tissue, metanephros |
| PTCH1 | 275 | ubiquitous | marker | tibia, dorsal root ganglion, trigeminal ganglion |
Protein interactions among cohort
Intra-cohort edges: 2.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| PTCH1 | 3,368 |
| FOXC1 | 2,896 |
| FRAS1 | 2,552 |
| PITX2 | 2,389 |
| FREM1 | 1,541 |
| DACT1 | 1,107 |
| CHST5 | 355 |
Intra-cohort edges
| A | B | Sources |
|---|---|---|
| FOXC1 | PITX2 | intact, string_interaction |
| FRAS1 | FREM1 | string_interaction |
Structural data
PDB: 2 · AlphaFold-only: 5 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| PTCH1 | Q13635 | 16 |
| PITX2 | Q99697 | 3 |
AlphaFold-only cohort genes (top 30 by pLDDT)
| Symbol | UniProt | pLDDT |
|---|---|---|
| CHST5 | Q9GZS9 | 88.60 |
| FREM1 | Q5H8C1 | 75.75 |
| FOXC1 | Q12948 | 56.09 |
| DACT1 | Q9NYF0 | 50.95 |
| FRAS1 | Q86XX4 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 11. Enrichment computed across 7 evidence-associated genes (5 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 5 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| TFAP2 (AP-2) family regulates transcription of other transcription factors | 1 | 571.0× | 0.010 | PITX2 |
| GLI proteins bind promoters of Hh responsive genes to promote transcription | 1 | 326.3× | 0.010 | PTCH1 |
| Ligand-receptor interactions | 1 | 285.5× | 0.010 | PTCH1 |
| Formation of intermediate mesoderm | 1 | 285.5× | 0.010 | FOXC1 |
| Activation of SMO | 1 | 126.9× | 0.017 | PTCH1 |
| Formation of the ureteric bud | 1 | 99.3× | 0.018 | FOXC1 |
| Keratan sulfate biosynthesis | 1 | 76.1× | 0.021 | CHST5 |
| Degradation of DVL | 1 | 47.6× | 0.029 | DACT1 |
| Class B/2 (Secretin family receptors) | 1 | 38.1× | 0.030 | PTCH1 |
| Hedgehog ‘off’ state | 1 | 35.7× | 0.030 | PTCH1 |
| Hedgehog ‘on’ state | 1 | 31.7× | 0.031 | PTCH1 |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 7 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| anatomical structure morphogenesis | 4 | 79.6× | 1e-05 | PITX2, FRAS1, FREM1, FOXC1 |
| cell communication | 2 | 240.7× | 0.002 | FRAS1, FREM1 |
| in utero embryonic development | 3 | 30.9× | 0.005 | PITX2, FOXC1, PTCH1 |
| embryonic limb morphogenesis | 2 | 114.6× | 0.005 | FRAS1, PTCH1 |
| camera-type eye development | 2 | 102.4× | 0.005 | PITX2, FOXC1 |
| subthalamic nucleus development | 1 | 2407.4× | 0.007 | PITX2 |
| superior vena cava morphogenesis | 1 | 2407.4× | 0.007 | PITX2 |
| glomerular epithelium development | 1 | 2407.4× | 0.007 | FOXC1 |
| positive regulation of hematopoietic stem cell differentiation | 1 | 2407.4× | 0.007 | FOXC1 |
| apoptotic process involved in outflow tract morphogenesis | 1 | 1203.7× | 0.007 | FOXC1 |
| response to chlorate | 1 | 1203.7× | 0.007 | PTCH1 |
| hypothalamus cell migration | 1 | 1203.7× | 0.007 | PITX2 |
| neural plate axis specification | 1 | 1203.7× | 0.007 | PTCH1 |
| prolactin secreting cell differentiation | 1 | 1203.7× | 0.007 | PITX2 |
| left lung morphogenesis | 1 | 1203.7× | 0.007 | PITX2 |
| pulmonary vein morphogenesis | 1 | 1203.7× | 0.007 | PITX2 |
| cell proliferation involved in outflow tract morphogenesis | 1 | 1203.7× | 0.007 | PITX2 |
| cell proliferation involved in metanephros development | 1 | 1203.7× | 0.007 | PTCH1 |
| negative regulation of apoptotic process involved in outflow tract morphogenesis | 1 | 1203.7× | 0.007 | FOXC1 |
| positive regulation of core promoter binding | 1 | 1203.7× | 0.007 | FOXC1 |
| negative regulation of transcription by RNA polymerase II | 4 | 10.1× | 0.007 | PITX2, DACT1, FOXC1, PTCH1 |
| pulmonary myocardium development | 1 | 802.5× | 0.007 | PITX2 |
| protein sulfation | 1 | 802.5× | 0.007 | CHST5 |
| vascular associated smooth muscle cell differentiation | 1 | 802.5× | 0.007 | PITX2 |
| deltoid tuberosity development | 1 | 802.5× | 0.007 | PITX2 |
| embryonic hindgut morphogenesis | 1 | 802.5× | 0.007 | DACT1 |
| cell differentiation involved in kidney development | 1 | 802.5× | 0.007 | PTCH1 |
| endodermal digestive tract morphogenesis | 1 | 802.5× | 0.007 | PITX2 |
| negative regulation of lymphangiogenesis | 1 | 802.5× | 0.007 | FOXC1 |
| positive regulation of hematopoietic progenitor cell differentiation | 1 | 802.5× | 0.007 | FOXC1 |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 7
Druggability breadth: 1 of 7 evidence-associated genes (14%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| PITX2 | 0 | 0 |
| FOXC1 | 0 | 0 |
| DACT1 | 0 | 0 |
| FRAS1 | 0 | 0 |
| CHST5 | 0 | 0 |
| FREM1 | 0 | 0 |
| PTCH1 | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Cohort genes with ChEMBL bioactivity (full, sorted by assay count)
| Symbol | Assays | Type breakdown |
|---|---|---|
| PTCH1 | 4 | Binding:4 |
Pharmacogenomics
Cohort genes with a PharmGKB record: 7; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 7 | PITX2, FOXC1, DACT1, FRAS1, CHST5, FREM1, PTCH1 |
Undrugged target profiles
7 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| PITX2 | 0 | — |
| FOXC1 | 0 | — |
| DACT1 | 0 | — |
| FRAS1 | 0 | — |
| CHST5 | 0 | — |
| FREM1 | 0 | — |
| PTCH1 | 4 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.